Pancreatic Cancer Research

ResearcherNanjing General Hospital of Nanjing Military CommandActive in the last 2 years

Xinbo Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8524-9662; OpenAlex author ID A5100762075. Sources: ClinicalTrials.gov.

Their work

Papers
6 (first author 2, last author 1)
Trials
2
Grants
0
Labs led
0
Collaborators
14
Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: 1 trial · 2025: 4 papers, 1 trial · 2026: 1 paper

Papers 6

  1. The life cycle of tertiary lymphoid structures in pancreatic cancer-a window of opportunity for immunotherapy. Last author DOI 10.3389/fimmu.2026.1784463↗
  2. Pancreatic Cancer-Derived Extracellular Vesicles Enriched with miR-223-5p Promote Skeletal Muscle Wasting Associated with Cachexia. Co-author DOI 10.1002/advs.202504064↗
  3. Family caregivers' needs at 6 months after pancreatic cancer surgery: A latent profile analysis. Co-author DOI 10.1016/j.ijnsa.2025.100416↗
  4. IND-Enabling Studies for a TCR-T Targeting a Pancreatic Cancer KRASG12V Mutation. Co-author DOI 10.1158/1078-0432.ccr-24-3086↗
  5. Synergic value of 3D CT-derived body composition and triglyceride glucose body mass for survival prognostic modeling in unresectable pancreatic cancer. First author DOI 10.3389/fnut.2025.1499188↗
  6. Long Noncoding RNA CERS6-AS1 Accelerates the Proliferation and Migration of Pancreatic Cancer Cells by Sequestering MicroRNA-15a-5p and MicroRNA-6838-5p and Mo… First author DOI 10.1097/mpa.0000000000001806↗

Trials 2

  1. Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer Study director NCT06177522↗
  2. Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer Study director NCT06326736↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rongxi Shen · 3 shared papers, 2021–2025 · strength 0.63
  2. Yimin Chen · 2 shared papers, 2025–2026 · strength 0.62
  3. Xinying Wang · 2 shared papers, 2025 · strength 0.52
  4. Kangjing Xu · 2 shared papers, 2025 · strength 0.52
  5. Sizhen Wang · 2 shared papers, 2021–2025 · strength 0.36
  6. Changsheng Zhou · 1 shared paper, 2025 · strength 0.26
  7. Xiaoxuan Li · 1 shared paper, 2025 · strength 0.24
  8. Xiaoping Fang · 1 shared paper, 2025 · strength 0.24
  9. Linglong Liu · 1 shared paper, 2025 · strength 0.24
  10. Mingxia Chen · 1 shared paper, 2025 · strength 0.24
  11. Hong‐Ming Hu · 1 shared paper, 2025 · strength 0.19
  12. Yonghao Ouyang · 1 shared paper, 2025 · strength 0.19
  13. Min Li · 1 shared paper, 2021 · strength 0.17
  14. Daojun Zhu · 1 shared paper, 2021 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.